Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies

Table 2 Summary of Subject Follow-up

	Study
	LYCS	S012	S013	All
Weeks From Baseline to Last ADHDRS-IV-PI Assessment
N†	102	198	20	320
Mean (SE)	42.7 (1.63)	11.5 (0.23)	22.5 (1.64)	22.2 (0.97)
Median	51.3	12.9	25.9	13.3
Range	3.9-58.0	1.0-17.3	4.4-27.1	1.0-58.0
Weeks From Baseline to Last CGI-ADHD-S Assessment
N†	102	206	21	329
Mean (SE)	43.1 (0.15)	11.2 (0.25)	21.5 (1.9)	21.7 (0.96)
Median	51.3	12.7	25.9	13.3
Range	2.3-58.0	1.0-17.3	1.6-27.1	1.0-58.0

†Only study participants with both a baseline value and at least one post-baseline value were included in this summary.
ADHDRS-IV-PI = Attention-Deficit/Hyperactivity Disorder Rating Scale Parent Version: Investigator Administered and Scored; CGI-ADHD-S = Clinical Global Impression of ADHD Severity.

ISSN: 1753-2000